Its the CDH17 study (only, I thought) where the dose escalation of 3/3 and 5/5 is now on the presentation slides.
What it suggests to me is that the maximum dose for CDH17 has yet to be determined. Whether the number of DLTs is zero or one at Dose 3 is an unknown. It could be exactly as in the example below and the optimal dose is somewhere between Dose 2 and 3. Its possible, isn't it, that the 5/5 design is being implemented due to either of the aforementioned reasons?
The last statement provided by ChatGPT is precisely what we should be expecting of a well managed trial. Maybe I shouldn't begrudge our CMO's rem or health insurance bill.
Its the CDH17 study (only, I thought) where the dose escalation...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |